Drug Profile
P 9808
Alternative Names: Porphogen; PorphozymLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Zymenex A/S
- Class
- Mechanism of Action Enzyme replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Acute intermittent porphyria
Most Recent Events
- 01 Apr 2006 P 9808 is available for licensing (http://www.zymenex.com)
- 01 Apr 2006 Discontinued - Preclinical for Acute intermittent porphyria in Sweden (SC)
- 01 Apr 2006 Discontinued - Phase-II for Acute intermittent porphyria in Sweden (IV)